Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
Almost all patients with prostate cancer progress to metastatic castration-resistant prostate cancer (mCRPC) despite initial responses. In cases where traditional first-line treatments prove ineffective, the potential of immune checkpoint blockade (ICB) therapy emerges as a promising approach for ma...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2024.2426755 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544794948141056 |
|---|---|
| author | Zixi Wu Junbiao Zhang Le Li Zhihua Wang Chunguang Yang |
| author_facet | Zixi Wu Junbiao Zhang Le Li Zhihua Wang Chunguang Yang |
| author_sort | Zixi Wu |
| collection | DOAJ |
| description | Almost all patients with prostate cancer progress to metastatic castration-resistant prostate cancer (mCRPC) despite initial responses. In cases where traditional first-line treatments prove ineffective, the potential of immune checkpoint blockade (ICB) therapy emerges as a promising approach for managing mCRPC. However, while immune checkpoint inhibitor monotherapy or combination therapy targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and/or programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) axis has been regarded as the standard therapy in many solid tumours, mCRPC as ‘cold’ tumours are considered to be relatively resistant to ICB treatment. Encouragingly, recent evidence suggests that ICB therapy may be particularly beneficial in specific subgroups of patients with high PD-L1 tumour expression, high tumour mutational burden or high tumour microsatellite instability/mismatch repair deficiency. Better understanding of these predictive biomarkers could screen which patients are most likely to benefit. This review article examines biomarkers for screening patients potentially effective in immune checkpoint inhibitor therapy. |
| format | Article |
| id | doaj-art-fcb947f6f79940f7a06abd04b9f919e8 |
| institution | Kabale University |
| issn | 0785-3890 1365-2060 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj-art-fcb947f6f79940f7a06abd04b9f919e82025-02-03T09:56:30ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2024.2426755Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitorsZixi Wu0Junbiao Zhang1Le Li2Zhihua Wang3Chunguang Yang4Department of Urology, Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, ChinaDepartment of Urology, Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, ChinaDepartment of Urology, Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, ChinaDepartment of Urology, Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, ChinaDepartment of Urology, Tongji Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology (HUST), Wuhan, ChinaAlmost all patients with prostate cancer progress to metastatic castration-resistant prostate cancer (mCRPC) despite initial responses. In cases where traditional first-line treatments prove ineffective, the potential of immune checkpoint blockade (ICB) therapy emerges as a promising approach for managing mCRPC. However, while immune checkpoint inhibitor monotherapy or combination therapy targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and/or programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) axis has been regarded as the standard therapy in many solid tumours, mCRPC as ‘cold’ tumours are considered to be relatively resistant to ICB treatment. Encouragingly, recent evidence suggests that ICB therapy may be particularly beneficial in specific subgroups of patients with high PD-L1 tumour expression, high tumour mutational burden or high tumour microsatellite instability/mismatch repair deficiency. Better understanding of these predictive biomarkers could screen which patients are most likely to benefit. This review article examines biomarkers for screening patients potentially effective in immune checkpoint inhibitor therapy.https://www.tandfonline.com/doi/10.1080/07853890.2024.2426755Castration-resistant prostate cancerimmune checkpoint inhibitorbiomarkerPD-L1tumour mutational burdenmicrosatellite instability |
| spellingShingle | Zixi Wu Junbiao Zhang Le Li Zhihua Wang Chunguang Yang Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors Annals of Medicine Castration-resistant prostate cancer immune checkpoint inhibitor biomarker PD-L1 tumour mutational burden microsatellite instability |
| title | Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| title_full | Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| title_fullStr | Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| title_full_unstemmed | Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| title_short | Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| title_sort | biomarkers in metastatic castration resistant prostate cancer for efficiency of immune checkpoint inhibitors |
| topic | Castration-resistant prostate cancer immune checkpoint inhibitor biomarker PD-L1 tumour mutational burden microsatellite instability |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2024.2426755 |
| work_keys_str_mv | AT zixiwu biomarkersinmetastaticcastrationresistantprostatecancerforefficiencyofimmunecheckpointinhibitors AT junbiaozhang biomarkersinmetastaticcastrationresistantprostatecancerforefficiencyofimmunecheckpointinhibitors AT leli biomarkersinmetastaticcastrationresistantprostatecancerforefficiencyofimmunecheckpointinhibitors AT zhihuawang biomarkersinmetastaticcastrationresistantprostatecancerforefficiencyofimmunecheckpointinhibitors AT chunguangyang biomarkersinmetastaticcastrationresistantprostatecancerforefficiencyofimmunecheckpointinhibitors |